

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,192,914 B1  
APPLICATION NO. : 10/089525  
DATED : March 20, 2007  
INVENTOR(S) : Jamey D. Marth et al.

Page 1 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the claims, column 27, line 34, kindly change

- “1. A method for decreasing levels of vWF or FVIII in an animal, the method comprising administering to the animal an effective dose of an inhibitor of ST3Gal-IV sialyltransferase enzyme activity, wherein said inhibitor is an analog of a ST3Gal-IV substrate and said animal is suffering from atherosclerosis or a blood clotting disorder, and whereby levels of von Williebrand factor (vWF) or factor VIII (FVIII) in the animal are decreased.
2. The method of claim 1, wherein the method is performed in conjunction with administration of a drug for which blood clotting is a potential side effect.
3. The method of claim 2, wherein the ST3Gal-IV sialyltransferase inhibitor is administered before or simultaneously with the drug for which blood clotting is a potential side effect.
4. The method of claim 1, wherein the method is performed as a therapeutic measure against atherosclerosis.
5. The method of claim 4, wherein the atherosclerosis is associated with coronary artery disease or peripheral arterial disease.
6. The method of claim 1, wherein platelet formation is not significantly affected by administration of the ST3Gal-IV sialyltransferase inhibitor to the animal.
7. The method of claim 1, further comprising monitoring the animal for levels of vWF or FVIII.

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,192,914 B1  
APPLICATION NO. : 10/089525  
DATED : March 20, 2007  
INVENTOR(S) : Jamey D. Marth et al.

Page 2 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the claims, column 27, line 34, kindly change (cont'd)

8. The method of claim 7, further comprising adjusting the dose of the ST3Gal-IV sialyltransferase inhibitor to maintain vWF at a desired level.
9. The method of claim 2, wherein the drug for which blood clotting is a potential side effect is selected from the group consisting of an anti-cancer drug, a corticosteroid, raloxifene, and a birth control agent.
10. The method of claim 9, wherein the anti-cancer drug is tamoxifen.
11. The method of claim 9, wherein the birth control agent is an estrogen or a progestin.
12. A method for modulating levels of vWF or FVIII in an animal, the method comprising administering to the animal an effective dose of an inhibitor of ST3Gal-IV sialyltransferase enzyme activity, wherein said inhibitor is an analog of a ST3Gal-IV substrate and whereby levels of vWF or FVIII in the animal are decreased; and monitoring the animal for levels of vWF or FVIII.”

to

--1. A method for decreasing levels of vWF or FVIII in an animal, the method comprising administering

to the animal an effective dose of an inhibitor of ST3Gal-IV sialyltransferase enzyme activity, wherein said inhibitor is an analog of a ST3Gal-IV substrate and said animal is suffering from atherosclerosis or a blood clotting disorder, and whereby levels of von Williebrand factor (vWF) or factor VIII (FVIII) in the animal are decreased.

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,192,914 B1  
APPLICATION NO. : 10/089525  
DATED : March 20, 2007  
INVENTOR(S) : Jamey D. Marth et al.

Page 3 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

2. The method of claim 1, wherein the method is performed in conjunction with administration of a drug for which blood clotting is a potential side effect.  
In the claims, column 27, line 34 kindly change (cont'd)
3. The method of claim 2, wherein the ST3Gal-IV sialyltransferase inhibitor is administered before or simultaneously with the drug for which blood clotting is a potential side effect.
4. The method of claim 1, wherein the method is performed as a therapeutic measure against atherosclerosis.
5. The method of claim 4, wherein the atherosclerosis is associated with coronary artery disease or peripheral arterial disease.
6. The method of claim 1, further comprising monitoring the animal for levels of vWF or FVIII.
7. The method of claim 6, further comprising adjusting the dose of the ST3Gal-IV sialyltransferase inhibitor to maintain vWF at a desired level.
8. The method of claim 2, wherein the drug for which blood clotting is a potential side effect is selected from the group consisting of an anti-cancer drug, a corticosteroid, raloxifene, and a birth control agent.
9. The method of claim 8, wherein the anti-cancer drug is tamoxifen.
10. The method of claim 8, wherein the birth control agent is an estrogen or a progestin.

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,192,914 B1  
APPLICATION NO. : 10/089525  
DATED : March 20, 2007  
INVENTOR(S) : Jamey D. Marth et al.

Page 4 of 4


It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the claims, column 27, line 34 kindly change (cont'd)

11. A method for modulating levels of vWF or FVIII in an animal, the method comprising administering to the animal an effective dose of an inhibitor of ST3Gal-IV sialyltransferase enzyme activity, wherein said inhibitor is an analog of a ST3Gal-IV substrate and whereby levels of vWF or FVIII in the animal are decreased; and monitoring the animal for levels of vWF or FVIII.--

Signed and Sealed this

Third Day of July, 2007

A handwritten signature in black ink, reading "Jon W. Dudas". The signature is stylized, with a large, looped initial "J" and a distinct "D" at the end.

JON W. DUDAS  
*Director of the United States Patent and Trademark Office*